By Clinical Research Team
April 9, 2025 | This month’s episode of the Scope of Things covers the latest news on setting expectations for Phase II cancer trials, insights about dementia from the Nun Study, links between cardiovascular disease and mild cognitive impairment, the use of aspirin to prevent cancer spread, a clinical trial map to improve study access, and a naturally occurring molecule that rivals Ozempic in its weight loss potential, brought to you by host Deborah Borfitz.
Ravi Parikh, medical director of data and technology applications shared resource at Winship Cancer Institute of Emory University, joins in to discuss TrialTranslator, a novel AI platform he helped develop to translate clinical trial results to real world populations.
Phase 2 cancer drug trials
- Study in the Journal of the National Cancer Institute
Aspirin for preventing cancer spread
Molecule rivaling Ozempic
Ravi Parikh, M.D., Medical Director of the Data and Technology Applications Shared Resource, Winship Cancer Institute of Emory University
Ravi B. Parikh, MD, MPP, is a board-certified medical oncologist specializing in the treatment of genitourinary cancers. Dr. Parikh is an attending physician practicing at Winship Cancer Institute at Emory Midtown.
Dr. Parikh is an associate professor in the Department of Hematology and Medical Oncology at the Emory University School of Medicine. He serves as medical director of the Winship Data and Technology Applications Shared Resource at Winship Cancer Institute of Emory University. In this role, he is responsible for its overall strategic scientific management and operational oversight. He works closely with leadership to develop and integrate artificial intelligence (AI) applications to improve the care of Winship patients with cancer.
Dr. Parikh received his medical degree at Harvard Medical School and his Master of Public Policy at the John F. Kennedy School of Government. He completed his residency in internal medicine at Brigham and Women’s Hospital and his fellowship in hematology and oncology at the University of Pennsylvania.